1. Phylogeny  
   IRAK4 is a member of the interleukin‐1 receptor‐associated kinase (IRAK) family, which includes IRAK1, IRAK2, and the inactive IRAK-M. In evolutionary terms, IRAK4 can be traced to the ancient serine/threonine kinase machinery that is conserved from invertebrates to vertebrates, sharing a close relationship with the Drosophila Pelle protein that functions in Toll signaling, and is classified among the kinases that emerged in early eukaryotic evolution (janssens2003functionaldiversityand pages 1-2). Studies of the human kinome, as detailed by Manning et al. (2002), place IRAK4 within the core set of protein kinases responsible for mediating innate immune responses; its conservation across species underlines its essential role in host defense mechanisms (janssens2003functionaldiversityand pages 2-3). IRAK4 orthologs are present in all examined mammalian species, and its evolutionary relationships reveal that — while the broader IRAK family maintains a common domain organization – only IRAK1 and IRAK4 possess demonstrable catalytic activity, emphasizing the specialized and non‐redundant function of IRAK4 in signaling cascades (janssens2003functionaldiversityand pages 6-7).
2. Reaction Catalyzed  
   IRAK4 is an ATP-dependent serine/threonine kinase that catalyzes the transfer of a phosphoryl group from ATP to hydroxyl groups on serine or threonine residues of its substrates. In biochemical terms, the reaction can be summarized as follows:  
     ATP + [protein] – OH → ADP + [protein] – O–PO3^2– + H^+  
   This reaction is exemplified by IRAK4’s phosphorylation of downstream targets, notably IRAK1, Pellino proteins, and TIRAP, which serve to propagate the signal from activated Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R) (bahia2015interleukin1receptorassociated pages 1-2).
3. Cofactor Requirements  
   The catalytic activity of IRAK4, like that of other serine/threonine kinases, depends on the presence of divalent metal ion cofactors. In most in vitro and cellular contexts, Mg^2+ is required to correctly orient ATP for the phosphoryl transfer reaction, thereby facilitating efficient kinase activity (bahia2015interleukin1receptorassociated pages 5-8).
4. Substrate Specificity  
   IRAK4 preferentially phosphorylates serine and threonine residues on its substrates. Its physiological substrates include IRAK1, which is phosphorylated in an initial trans-phosphorylation event that triggers its autophosphorylation and subsequent recruitment of additional signaling molecules, as well as Pellino proteins that modulate downstream ubiquitination events. Although the explicit consensus motif has not been fully delineated, information from large-scale profiling of serine/threonine kinases indicates that many kinases in this category preferentially target substrates containing a modest consensus motif involving basic residues preceding the phospho-acceptor site; however, for IRAK4 the emphasis is on its ability to modify strategically positioned serine/threonine sites that regulate protein–protein interactions within the Myddosome (bahia2015interleukin1receptorassociated pages 3-4, chaudhary2015recentadvancesin pages 3-4, Johnson2023Atlas of substrate specificities for the human serine/threonine kinome).
5. Structure  
   The three-dimensional structure of IRAK4 has been investigated both through X-ray crystallography and advanced computational modeling. The protein comprises 460 amino acids, corresponding to a molecular mass of approximately 52 kDa, and its domain organization includes an N-terminal death domain (DD) that mediates homotypic interactions with the adaptor protein MyD88, and a central kinase domain (KD) that is responsible for its catalytic function. Structural studies reveal that the kinase domain adopts a classical bilobal fold typical of serine/threonine kinases, with a smaller N-terminal lobe predominantly composed of β-sheets and a larger C-terminal lobe composed mainly of α-helices (bahia2015interleukin1receptorassociated pages 3-4, flannery2010theinterleukin1receptorassociated pages 43-47). Key catalytic features within the kinase domain include the invariant lysine residue (K213), crucial for ATP binding, and an essential glutamate within the helix αC (E233), which forms a salt bridge with K213. Additionally, a unique tyrosine residue (Y262) acts as a gatekeeper, modulating access to an internal hydrophobic pocket that is targeted by selective small-molecule inhibitors (bahia2015interleukin1receptorassociated pages 5-8, kuglstatter2007cuttingedgeil1 pages 1-2). The flexible activation loop, which undergoes autophosphorylation at critical residues (such as T342, T345, and S346), modulates the conformational state of the kinase, switching it between inactive (helix C-out) and active (helix C-in) conformations (bahia2015interleukin1receptorassociated pages 3-4, patra2016recentprogressin pages 13-15).
6. Regulation  
   The regulation of IRAK4 occurs at multiple levels through both intrinsic mechanisms and interactions with other signaling molecules. IRAK4 is rapidly recruited to the receptor complex upon TLR or IL-1R activation via homotypic death domain interactions with MyD88, a process which facilitates its dimerization and subsequent trans-autophosphorylation. Critical autophosphorylation events within the activation loop, including at residues T342, T345, and S346, are required for its catalytic activity and select downstream signaling (bahia2015interleukin1receptorassociated pages 3-4, fraczek2008thekinaseactivity pages 3-4). In addition, IRAK4 phosphorylates other targets such as IRAK1 and Pellino proteins to propagate the signaling cascade leading to NF-κB activation (bahia2015interleukin1receptorassociated pages 8-11). The kinase is also subject to regulation through ubiquitination processes that facilitate the formation and disassembly of the signaling complex; for example, phosphorylation of TIRAP can promote its subsequent ubiquitination and degradation, thereby modulating signal intensity (cushing2014interleukin1tolllikereceptorinduced pages 10-11, de2018mechanismofdysfunction pages 12-13). Conformational changes such as the shift from a helix C-out to a helix C-in state contribute to IRAK4’s regulation by controlling the accessibility of its active site (bahia2015interleukin1receptorassociated pages 5-8). These mechanisms collectively ensure that IRAK4 activity is tightly controlled in a cell type–specific manner, as evidenced by differential effects observed in primary human monocytes versus dermal fibroblasts (cushing2014interleukin1tolllikereceptorinduced pages 8-9).
7. Function  
   IRAK4 plays a central role in initiating innate immune responses by acting as the primary kinase downstream of IL-1Rs and most TLRs. Once these receptors are engaged by their respective ligands (such as IL-1 or lipopolysaccharide), MyD88 is recruited to form the Myddosome complex together with IRAK4 and IRAK2. Within this complex, IRAK4 phosphorylates IRAK1, thereby triggering its autophosphorylation and the subsequent engagement of TRAF6. This series of phosphorylation events ultimately leads to the activation of mitogen-activated protein kinases (MAPKs) as well as the IKK complex, culminating in the nuclear translocation and activation of NF-κB and the production of pro-inflammatory cytokines (bahia2015interleukin1receptorassociated pages 1-2, bahia2015interleukin1receptorassociated pages 8-11). In addition to mediating cytokine expression, IRAK4 phosphorylates Pellino proteins, which are E3 ubiquitin ligases involved in the polyubiquitination of IRAK1; this modification is important for bridging the IRAK1-MAP3K7/TAK1-TRAF6 complex with the IKK complex (bahia2015interleukin1receptorassociated pages 1-2). Furthermore, IRAK4 has been linked to the regulation of NADPH oxidase activity via phosphorylation of NCF1, thus providing a connection between TLR-induced signaling and the oxidative burst during microbial infections (bahia2015interleukin1receptorassociated pages 1-2). Expression studies have shown that IRAK4 is ubiquitously expressed across various tissues and immune cell types, including monocytes, macrophages, dendritic cells, and lymphocytes, which underscores its importance in both the innate and adaptive arms of the immune system (chaudhary2015recentadvancesin pages 1-2). Its involvement in the inflammatory signaling cascade also provides a molecular basis for its implication in a broad range of diseases, including autoimmune disorders, inflammatory diseases, and certain cancers (de2018mechanismofdysfunction pages 1-2).
8. Other Comments  
   Pharmacological targeting of IRAK4 has garnered significant interest due to its crucial role in innate immune signaling and its association with several inflammatory and autoimmune diseases. Several small-molecule inhibitors, including compounds such as PF-06650833 developed by Pfizer and various indoloquinoline and amidopyrazole derivatives from other pharmaceutical groups, have demonstrated potent IRAK4 inhibition with nanomolar IC50 values in enzyme assays, and some of these inhibitors have advanced into clinical trials for the treatment of conditions such as systemic lupus erythematosus and rheumatoid arthritis (seganish2016inhibitorsofinterleukin1 pages 19-22, wang2009irak4inhibitorsfor pages 12-12). In addition, highly selective dual inhibitors that target both IRAK1 and IRAK4 have been characterized in inflammatory models, enabling the dissection of distinct signaling functions between these kinases (scarneo2020ahighlyselective pages 1-2, seganish2016inhibitorsofinterleukin1 pages 1-6). Notably, genetic deficiency or loss-of-function mutations in IRAK4 are associated with primary immunodeficiencies in which affected individuals show increased susceptibility to pyogenic bacterial infections, especially during childhood (ringwood2008theinvolvementof pages 5-6, de2018mechanismofdysfunction pages 1-2). These clinical observations reinforce the role of IRAK4 as a key mediator in host defense. Overall, the unique biochemical and regulatory properties of IRAK4, including its distinct activation mechanism via autophosphorylation and its immediate upstream role in assembling Myddosome complexes, have made it a promising target for therapeutic intervention in conditions driven by dysregulated inflammatory responses (cushing2014interleukin1tolllikereceptorinduced pages 11-11, patra2016recentprogressin pages 12-13).
9. References

* bahia2015interleukin1receptorassociated pages 1-2
* bahia2015interleukin1receptorassociated pages 2-3
* bahia2015interleukin1receptorassociated pages 3-4
* bahia2015interleukin1receptorassociated pages 5-8
* bahia2015interleukin1receptorassociated pages 8-11
* chaudhary2015recentadvancesin pages 1-2
* chaudhary2015recentadvancesin pages 3-4
* cushing2014interleukin1tolllikereceptorinduced pages 11-11
* cushing2014interleukin1tolllikereceptorinduced pages 2-3
* flannery2010theinterleukin1receptorassociated pages 20-24
* flannery2010theinterleukin1receptorassociated pages 24-28
* flannery2010theinterleukin1receptorassociated pages 43-47
* flannery2010theinterleukin1receptorassociated pages 5-9
* genung2017smallmoleculeinhibition pages 1-5
* genung2017smallmoleculeinhibition pages 38-41
* genung2017smallmoleculeinhibition pages 5-8
* hynes2014advancesinthe pages 1-5
* kuglstatter2007cuttingedgeil1 pages 1-2
* patra2016recentprogressin pages 1-3
* patra2016recentprogressin pages 10-12
* patra2016recentprogressin pages 12-13
* patra2016recentprogressin pages 13-15
* patra2016recentprogressin pages 3-6
* patra2016recentprogressin pages 8-10
* ringwood2008theinvolvementof pages 5-6
* seganish2016inhibitorsofinterleukin1 pages 22-26
* song2009thekinaseactivities pages 9-9
* vollmer2017themechanismof pages 1-3
* wang2009irak4inhibitorsfor pages 1-2
* wang2009irak4inhibitorsfor pages 12-12
* wang2009irak4inhibitorsfor pages 2-3
* cushing2014interleukin1tolllikereceptorinduced pages 1-2
* cushing2014interleukin1tolllikereceptorinduced pages 10-11
* cushing2014interleukin1tolllikereceptorinduced pages 8-9
* de2018mechanismofdysfunction pages 1-2
* de2018mechanismofdysfunction pages 12-13
* flannery2010theinterleukin1receptorassociated pages 1-5
* fraczek2008thekinaseactivity pages 3-4
* fraczek2008thekinaseactivity pages 4-4
* fraczek2008thekinaseactivity pages 8-9
* genung2017smallmoleculeinhibition pages 8-10
* janssens2003functionaldiversityand pages 1-2
* janssens2003functionaldiversityand pages 2-3
* janssens2003functionaldiversityand pages 6-7
* kim2024recentadvancesin pages 1-3
* kim2024recentadvancesin pages 12-14
* ringwood2008theinvolvementof pages 6-8
* scarneo2020ahighlyselective pages 1-2
* seganish2016inhibitorsofinterleukin1 pages 1-6
* seganish2016inhibitorsofinterleukin1 pages 19-22

References

1. (bahia2015interleukin1receptorassociated pages 1-2): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
2. (bahia2015interleukin1receptorassociated pages 2-3): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
3. (bahia2015interleukin1receptorassociated pages 3-4): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
4. (bahia2015interleukin1receptorassociated pages 5-8): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
5. (bahia2015interleukin1receptorassociated pages 8-11): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
6. (chaudhary2015recentadvancesin pages 1-2): Divya Chaudhary, Shaughnessy Robinson, and Donna L. Romero. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (irak4) as a therapeutic target for inflammation and oncology disorders. Journal of medicinal chemistry, 58 1:96-110, Jan 2015. URL: https://doi.org/10.1021/jm5016044, doi:10.1021/jm5016044. This article has 114 citations and is from a highest quality peer-reviewed journal.
7. (chaudhary2015recentadvancesin pages 3-4): Divya Chaudhary, Shaughnessy Robinson, and Donna L. Romero. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (irak4) as a therapeutic target for inflammation and oncology disorders. Journal of medicinal chemistry, 58 1:96-110, Jan 2015. URL: https://doi.org/10.1021/jm5016044, doi:10.1021/jm5016044. This article has 114 citations and is from a highest quality peer-reviewed journal.
8. (cushing2014interleukin1tolllikereceptorinduced pages 11-11): Leah Cushing, Wayne Stochaj, Marshall Siegel, Robert Czerwinski, Ken Dower, Quentin Wright, Margaret Hirschfield, Jean-Laurent Casanova, Capucine Picard, Anne Puel, Lih-Ling Lin, and Vikram R. Rao. Interleukin 1/toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner. Journal of Biological Chemistry, 289:10865-10875, Apr 2014. URL: https://doi.org/10.1074/jbc.m113.544809, doi:10.1074/jbc.m113.544809. This article has 69 citations and is from a domain leading peer-reviewed journal.
9. (cushing2014interleukin1tolllikereceptorinduced pages 2-3): Leah Cushing, Wayne Stochaj, Marshall Siegel, Robert Czerwinski, Ken Dower, Quentin Wright, Margaret Hirschfield, Jean-Laurent Casanova, Capucine Picard, Anne Puel, Lih-Ling Lin, and Vikram R. Rao. Interleukin 1/toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner. Journal of Biological Chemistry, 289:10865-10875, Apr 2014. URL: https://doi.org/10.1074/jbc.m113.544809, doi:10.1074/jbc.m113.544809. This article has 69 citations and is from a domain leading peer-reviewed journal.
10. (flannery2010theinterleukin1receptorassociated pages 20-24): Sinead Flannery and Andrew G. Bowie. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochemical Pharmacology, 80:1981-1991, Dec 2010. URL: https://doi.org/10.1016/j.bcp.2010.06.020, doi:10.1016/j.bcp.2010.06.020. This article has 392 citations and is from a domain leading peer-reviewed journal.
11. (flannery2010theinterleukin1receptorassociated pages 24-28): Sinead Flannery and Andrew G. Bowie. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochemical Pharmacology, 80:1981-1991, Dec 2010. URL: https://doi.org/10.1016/j.bcp.2010.06.020, doi:10.1016/j.bcp.2010.06.020. This article has 392 citations and is from a domain leading peer-reviewed journal.
12. (flannery2010theinterleukin1receptorassociated pages 43-47): Sinead Flannery and Andrew G. Bowie. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochemical Pharmacology, 80:1981-1991, Dec 2010. URL: https://doi.org/10.1016/j.bcp.2010.06.020, doi:10.1016/j.bcp.2010.06.020. This article has 392 citations and is from a domain leading peer-reviewed journal.
13. (flannery2010theinterleukin1receptorassociated pages 5-9): Sinead Flannery and Andrew G. Bowie. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochemical Pharmacology, 80:1981-1991, Dec 2010. URL: https://doi.org/10.1016/j.bcp.2010.06.020, doi:10.1016/j.bcp.2010.06.020. This article has 392 citations and is from a domain leading peer-reviewed journal.
14. (genung2017smallmoleculeinhibition pages 1-5): N.E. Genung and K.M. Guckian. Small molecule inhibition of interleukin-1 receptor-associated kinase 4 (irak4). Progress in Medicinal Chemistry, 56:117-163, Jan 2017. URL: https://doi.org/10.1016/bs.pmch.2016.11.004, doi:10.1016/bs.pmch.2016.11.004. This article has 24 citations and is from a peer-reviewed journal.
15. (genung2017smallmoleculeinhibition pages 38-41): N.E. Genung and K.M. Guckian. Small molecule inhibition of interleukin-1 receptor-associated kinase 4 (irak4). Progress in Medicinal Chemistry, 56:117-163, Jan 2017. URL: https://doi.org/10.1016/bs.pmch.2016.11.004, doi:10.1016/bs.pmch.2016.11.004. This article has 24 citations and is from a peer-reviewed journal.
16. (genung2017smallmoleculeinhibition pages 5-8): N.E. Genung and K.M. Guckian. Small molecule inhibition of interleukin-1 receptor-associated kinase 4 (irak4). Progress in Medicinal Chemistry, 56:117-163, Jan 2017. URL: https://doi.org/10.1016/bs.pmch.2016.11.004, doi:10.1016/bs.pmch.2016.11.004. This article has 24 citations and is from a peer-reviewed journal.
17. (hynes2014advancesinthe pages 1-5): John Hynes and Satheesh K. Nair. Advances in the discovery of small-molecule irak4 inhibitors. Annual Reports in Medicinal Chemistry, pages 117-133, Jan 2014. URL: https://doi.org/10.1016/b978-0-12-800167-7.00009-2, doi:10.1016/b978-0-12-800167-7.00009-2. This article has 35 citations and is from a peer-reviewed journal.
18. (kuglstatter2007cuttingedgeil1 pages 1-2): Andreas Kuglstatter, Armando G. Villaseñor, David Shaw, Simon W. Lee, Stan Tsing, Linghao Niu, Kyung W. Song, Jim W. Barnett, and Michelle F. Browner. Cutting edge: il-1 receptor-associated kinase 4 structures reveal novel features and multiple conformations. The Journal of Immunology, 178:2641-2645, Mar 2007. URL: https://doi.org/10.4049/jimmunol.178.5.2641, doi:10.4049/jimmunol.178.5.2641. This article has 92 citations.
19. (patra2016recentprogressin pages 1-3): Mahesh Patra and Sangdun Choi. Recent progress in the molecular recognition and therapeutic importance of interleukin-1 receptor-associated kinase 4. Molecules, 21:1529, Nov 2016. URL: https://doi.org/10.3390/molecules21111529, doi:10.3390/molecules21111529. This article has 43 citations and is from a peer-reviewed journal.
20. (patra2016recentprogressin pages 10-12): Mahesh Patra and Sangdun Choi. Recent progress in the molecular recognition and therapeutic importance of interleukin-1 receptor-associated kinase 4. Molecules, 21:1529, Nov 2016. URL: https://doi.org/10.3390/molecules21111529, doi:10.3390/molecules21111529. This article has 43 citations and is from a peer-reviewed journal.
21. (patra2016recentprogressin pages 12-13): Mahesh Patra and Sangdun Choi. Recent progress in the molecular recognition and therapeutic importance of interleukin-1 receptor-associated kinase 4. Molecules, 21:1529, Nov 2016. URL: https://doi.org/10.3390/molecules21111529, doi:10.3390/molecules21111529. This article has 43 citations and is from a peer-reviewed journal.
22. (patra2016recentprogressin pages 13-15): Mahesh Patra and Sangdun Choi. Recent progress in the molecular recognition and therapeutic importance of interleukin-1 receptor-associated kinase 4. Molecules, 21:1529, Nov 2016. URL: https://doi.org/10.3390/molecules21111529, doi:10.3390/molecules21111529. This article has 43 citations and is from a peer-reviewed journal.
23. (patra2016recentprogressin pages 3-6): Mahesh Patra and Sangdun Choi. Recent progress in the molecular recognition and therapeutic importance of interleukin-1 receptor-associated kinase 4. Molecules, 21:1529, Nov 2016. URL: https://doi.org/10.3390/molecules21111529, doi:10.3390/molecules21111529. This article has 43 citations and is from a peer-reviewed journal.
24. (patra2016recentprogressin pages 8-10): Mahesh Patra and Sangdun Choi. Recent progress in the molecular recognition and therapeutic importance of interleukin-1 receptor-associated kinase 4. Molecules, 21:1529, Nov 2016. URL: https://doi.org/10.3390/molecules21111529, doi:10.3390/molecules21111529. This article has 43 citations and is from a peer-reviewed journal.
25. (ringwood2008theinvolvementof pages 5-6): Lorna Ringwood and Liwu Li. The involvement of the interleukin-1 receptor-associated kinases (iraks) in cellular signaling networks controlling inflammation. Cytokine, 42:1-7, Apr 2008. URL: https://doi.org/10.1016/j.cyto.2007.12.012, doi:10.1016/j.cyto.2007.12.012. This article has 104 citations and is from a peer-reviewed journal.
26. (seganish2016inhibitorsofinterleukin1 pages 22-26): W. Michael Seganish. Inhibitors of interleukin-1 receptor-associated kinase 4 (irak4): a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 26:917-932, Jun 2016. URL: https://doi.org/10.1080/13543776.2016.1202926, doi:10.1080/13543776.2016.1202926. This article has 37 citations and is from a peer-reviewed journal.
27. (song2009thekinaseactivities pages 9-9): Kyung W. Song, Francisco X. Talamas, Rebecca T. Suttmann, Pam S. Olson, Jim W. Barnett, Simon W. Lee, Kelly D. Thompson, Sue Jin, Mohammad Hekmat-Nejad, Terrence Z. Cai, Anthony M. Manning, Ronald J. Hill, and Brian R. Wong. The kinase activities of interleukin-1 receptor associated kinase (irak)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cells. Molecular Immunology, 46:1458-1466, Apr 2009. URL: https://doi.org/10.1016/j.molimm.2008.12.012, doi:10.1016/j.molimm.2008.12.012. This article has 89 citations and is from a peer-reviewed journal.
28. (vollmer2017themechanismof pages 1-3): Stefan Vollmer, Sam Strickson, Tinghu Zhang, Nathanael Gray, Katherine L. Lee, Vikram R. Rao, and Philip Cohen. The mechanism of activation of irak1 and irak4 by interleukin-1 and toll-like receptor agonists. Biochemical Journal, 474:2027-2038, Jun 2017. URL: https://doi.org/10.1042/bcj20170097, doi:10.1042/bcj20170097. This article has 105 citations and is from a domain leading peer-reviewed journal.
29. (wang2009irak4inhibitorsfor pages 1-2): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.
30. (wang2009irak4inhibitorsfor pages 12-12): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.
31. (wang2009irak4inhibitorsfor pages 2-3): Zhulun Wang, Holger Wesche, Tracey Stevens, Nigel Walker, and Wen-Chen Yeh. Irak-4 inhibitors for inflammation. Current Topics in Medicinal Chemistry, 9:724-737, May 2009. URL: https://doi.org/10.2174/156802609789044407, doi:10.2174/156802609789044407. This article has 183 citations and is from a peer-reviewed journal.
32. (cushing2014interleukin1tolllikereceptorinduced pages 1-2): Leah Cushing, Wayne Stochaj, Marshall Siegel, Robert Czerwinski, Ken Dower, Quentin Wright, Margaret Hirschfield, Jean-Laurent Casanova, Capucine Picard, Anne Puel, Lih-Ling Lin, and Vikram R. Rao. Interleukin 1/toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner. Journal of Biological Chemistry, 289:10865-10875, Apr 2014. URL: https://doi.org/10.1074/jbc.m113.544809, doi:10.1074/jbc.m113.544809. This article has 69 citations and is from a domain leading peer-reviewed journal.
33. (cushing2014interleukin1tolllikereceptorinduced pages 10-11): Leah Cushing, Wayne Stochaj, Marshall Siegel, Robert Czerwinski, Ken Dower, Quentin Wright, Margaret Hirschfield, Jean-Laurent Casanova, Capucine Picard, Anne Puel, Lih-Ling Lin, and Vikram R. Rao. Interleukin 1/toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner. Journal of Biological Chemistry, 289:10865-10875, Apr 2014. URL: https://doi.org/10.1074/jbc.m113.544809, doi:10.1074/jbc.m113.544809. This article has 69 citations and is from a domain leading peer-reviewed journal.
34. (cushing2014interleukin1tolllikereceptorinduced pages 8-9): Leah Cushing, Wayne Stochaj, Marshall Siegel, Robert Czerwinski, Ken Dower, Quentin Wright, Margaret Hirschfield, Jean-Laurent Casanova, Capucine Picard, Anne Puel, Lih-Ling Lin, and Vikram R. Rao. Interleukin 1/toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner. Journal of Biological Chemistry, 289:10865-10875, Apr 2014. URL: https://doi.org/10.1074/jbc.m113.544809, doi:10.1074/jbc.m113.544809. This article has 69 citations and is from a domain leading peer-reviewed journal.
35. (de2018mechanismofdysfunction pages 1-2): Saurav De, Fawziya Karim, Ezechielle Kiessu, Leah Cushing, Lih-Ling Lin, Pegah Ghandil, Cyrille Hoarau, Jean-Laurent Casanova, Anne Puel, and Vikram R. Rao. Mechanism of dysfunction of human variants of the irak4 kinase and a role for its kinase activity in interleukin-1 receptor signaling. Journal of Biological Chemistry, 293:15208-15220, Sep 2018. URL: https://doi.org/10.1074/jbc.ra118.003831, doi:10.1074/jbc.ra118.003831. This article has 44 citations and is from a domain leading peer-reviewed journal.
36. (de2018mechanismofdysfunction pages 12-13): Saurav De, Fawziya Karim, Ezechielle Kiessu, Leah Cushing, Lih-Ling Lin, Pegah Ghandil, Cyrille Hoarau, Jean-Laurent Casanova, Anne Puel, and Vikram R. Rao. Mechanism of dysfunction of human variants of the irak4 kinase and a role for its kinase activity in interleukin-1 receptor signaling. Journal of Biological Chemistry, 293:15208-15220, Sep 2018. URL: https://doi.org/10.1074/jbc.ra118.003831, doi:10.1074/jbc.ra118.003831. This article has 44 citations and is from a domain leading peer-reviewed journal.
37. (flannery2010theinterleukin1receptorassociated pages 1-5): Sinead Flannery and Andrew G. Bowie. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochemical Pharmacology, 80:1981-1991, Dec 2010. URL: https://doi.org/10.1016/j.bcp.2010.06.020, doi:10.1016/j.bcp.2010.06.020. This article has 392 citations and is from a domain leading peer-reviewed journal.
38. (fraczek2008thekinaseactivity pages 3-4): Jerzy Frączek, Tae Whan Kim, Hui Xiao, Jianhong Yao, Qian Wen, Yali Li, Jean-Laurent Casanova, Juliusz Pryjma, and Xiaoxia Li. The kinase activity of il-1 receptor-associated kinase 4 is required for interleukin-1 receptor/toll-like receptor-induced tak1-dependent nfκb activation. Journal of Biological Chemistry, 283:31697-31705, Nov 2008. URL: https://doi.org/10.1074/jbc.m804779200, doi:10.1074/jbc.m804779200. This article has 67 citations and is from a domain leading peer-reviewed journal.
39. (fraczek2008thekinaseactivity pages 4-4): Jerzy Frączek, Tae Whan Kim, Hui Xiao, Jianhong Yao, Qian Wen, Yali Li, Jean-Laurent Casanova, Juliusz Pryjma, and Xiaoxia Li. The kinase activity of il-1 receptor-associated kinase 4 is required for interleukin-1 receptor/toll-like receptor-induced tak1-dependent nfκb activation. Journal of Biological Chemistry, 283:31697-31705, Nov 2008. URL: https://doi.org/10.1074/jbc.m804779200, doi:10.1074/jbc.m804779200. This article has 67 citations and is from a domain leading peer-reviewed journal.
40. (fraczek2008thekinaseactivity pages 8-9): Jerzy Frączek, Tae Whan Kim, Hui Xiao, Jianhong Yao, Qian Wen, Yali Li, Jean-Laurent Casanova, Juliusz Pryjma, and Xiaoxia Li. The kinase activity of il-1 receptor-associated kinase 4 is required for interleukin-1 receptor/toll-like receptor-induced tak1-dependent nfκb activation. Journal of Biological Chemistry, 283:31697-31705, Nov 2008. URL: https://doi.org/10.1074/jbc.m804779200, doi:10.1074/jbc.m804779200. This article has 67 citations and is from a domain leading peer-reviewed journal.
41. (genung2017smallmoleculeinhibition pages 8-10): N.E. Genung and K.M. Guckian. Small molecule inhibition of interleukin-1 receptor-associated kinase 4 (irak4). Progress in Medicinal Chemistry, 56:117-163, Jan 2017. URL: https://doi.org/10.1016/bs.pmch.2016.11.004, doi:10.1016/bs.pmch.2016.11.004. This article has 24 citations and is from a peer-reviewed journal.
42. (janssens2003functionaldiversityand pages 1-2): Sophie Janssens and Rudi Beyaert. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (irak) family members. Molecular Cell, 11:293-302, Feb 2003. URL: https://doi.org/10.1016/s1097-2765(03)00053-4, doi:10.1016/s1097-2765(03)00053-4. This article has 756 citations and is from a highest quality peer-reviewed journal.
43. (janssens2003functionaldiversityand pages 2-3): Sophie Janssens and Rudi Beyaert. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (irak) family members. Molecular Cell, 11:293-302, Feb 2003. URL: https://doi.org/10.1016/s1097-2765(03)00053-4, doi:10.1016/s1097-2765(03)00053-4. This article has 756 citations and is from a highest quality peer-reviewed journal.
44. (janssens2003functionaldiversityand pages 6-7): Sophie Janssens and Rudi Beyaert. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (irak) family members. Molecular Cell, 11:293-302, Feb 2003. URL: https://doi.org/10.1016/s1097-2765(03)00053-4, doi:10.1016/s1097-2765(03)00053-4. This article has 756 citations and is from a highest quality peer-reviewed journal.
45. (kim2024recentadvancesin pages 1-3): Kyeong Min Kim, Na-Hee Hwang, Ja-Shil Hyun, and Dongyun Shin. Recent advances in irak1: pharmacological and therapeutic aspects. Molecules, 29:2226, May 2024. URL: https://doi.org/10.3390/molecules29102226, doi:10.3390/molecules29102226. This article has 6 citations and is from a peer-reviewed journal.
46. (kim2024recentadvancesin pages 12-14): Kyeong Min Kim, Na-Hee Hwang, Ja-Shil Hyun, and Dongyun Shin. Recent advances in irak1: pharmacological and therapeutic aspects. Molecules, 29:2226, May 2024. URL: https://doi.org/10.3390/molecules29102226, doi:10.3390/molecules29102226. This article has 6 citations and is from a peer-reviewed journal.
47. (ringwood2008theinvolvementof pages 6-8): Lorna Ringwood and Liwu Li. The involvement of the interleukin-1 receptor-associated kinases (iraks) in cellular signaling networks controlling inflammation. Cytokine, 42:1-7, Apr 2008. URL: https://doi.org/10.1016/j.cyto.2007.12.012, doi:10.1016/j.cyto.2007.12.012. This article has 104 citations and is from a peer-reviewed journal.
48. (scarneo2020ahighlyselective pages 1-2): Scott A. Scarneo, Philip F. Hughes, Kelly W. Yang, David A. Carlson, Deepak Gurbani, Kenneth D. Westover, and Timothy A.J. Haystead. A highly selective inhibitor of interleukin-1 receptor–associated kinases 1/4 (irak-1/4) delineates the distinct signaling roles of irak-1/4 and the tak1 kinase. Journal of Biological Chemistry, 295:1565-1574, Feb 2020. URL: https://doi.org/10.1074/jbc.ra119.011857, doi:10.1074/jbc.ra119.011857. This article has 30 citations and is from a domain leading peer-reviewed journal.
49. (seganish2016inhibitorsofinterleukin1 pages 1-6): W. Michael Seganish. Inhibitors of interleukin-1 receptor-associated kinase 4 (irak4): a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 26:917-932, Jun 2016. URL: https://doi.org/10.1080/13543776.2016.1202926, doi:10.1080/13543776.2016.1202926. This article has 37 citations and is from a peer-reviewed journal.
50. (seganish2016inhibitorsofinterleukin1 pages 19-22): W. Michael Seganish. Inhibitors of interleukin-1 receptor-associated kinase 4 (irak4): a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 26:917-932, Jun 2016. URL: https://doi.org/10.1080/13543776.2016.1202926, doi:10.1080/13543776.2016.1202926. This article has 37 citations and is from a peer-reviewed journal.